Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Trial Profile

A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emixustat (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms SEATTLE
  • Sponsors Acucela
  • Most Recent Events

    • 01 Oct 2018 According to results published in an Ophthalmology Journal, the number of subjects randomized to the 10 mg emixustat arm was less than the other arms because of a temporary suspension of enrollment in this arm due to concerns by the Data Monitoring Committee over decreases in LL-BCVA in some subjects.This issue was further investigated and on the basis of additional data, enrollment was resumed into this arm.
    • 13 Jun 2016 According to an Acucela Inc. media release, the company will discontinue further analysis of the clinical data from this study pertaining to geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
    • 31 May 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top